Abivax’s lead asset, obefazimod, has delivered robust results in ulcerative colitis, achieving a 65% clinical remission rate at week 12 in its Phase 2b trial and demonstrating sustained mucosal healing in over half of treated patients through week 48. With ulcerative colitis prevalence estimated at 900,000 in major markets and annual treatment costs exceeding $30,000 per patient, obefazimod’s differentiated mechanism targeting innate immunity positions Abivax to capture a multi-billion-dollar market share. Management projects peak global sales of $4–5 billion, supported by a favorable safety profile and once-daily oral dosing that could displace injectable biologics in both first- and second-line settings.

Recent media reports have reignited speculation that pharmaceutical giants such as Eli Lilly are preparing bids in the $15–18 billion range for Abivax. The stock climbed as much as 30% in early trading on news of a potential $17.5 billion offer, then surged 23% on renewed chatter that Lilly remains interested. While these developments underscore Abivax’s attractiveness as an acquisition target, the company has emphasized that strategic partnerships and licensing discussions remain exploratory, and that long-term value will be driven by obefazimod’s commercial success rather than near-term deal speculation.

Investors are focused on several key milestones next year. Topline data from the Phase 3 UC maintenance study are expected in mid-2026, a potential trigger for regulatory filings in both the US and EU. Management has guided for NDA and MAA submissions by year-end, subject to positive outcomes. Additionally, readouts from the Phase 2b Crohn’s disease trial are slated for Q3 2026, which could expand obefazimod’s label and address a market valued at over $8 billion annually. These catalysts will be critical in validating long-term revenue projections and may influence both share performance and acquisition interest.